Objective:To investigate the effects of Ateprase combined with Butylphthalide on antioxidant capacity, coagulation function and related factors in patients with cerebral infarction.Methods:A total of 80 patients with ...Objective:To investigate the effects of Ateprase combined with Butylphthalide on antioxidant capacity, coagulation function and related factors in patients with cerebral infarction.Methods:A total of 80 patients with cerebral infarction who were treated in department of Neurology of our hospital from June 2015 to June 2018 were randomly divided into control group and observation group, with 40 cases in each group. Patients in the control group were treated with Butylphthalidel, while patients in the observation group were treated with Ateprase combined with Butylphthalide. The levels of superoxide dismutase (SOD), serum malondialdehyde (MDA), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), vascular endothelial growth factor (VEGF), nitric oxide (NO), endothelin (ET-1), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) were measured and compared before and after treatment.Results: After treatment: the levels of SOD, APTT, PT, TT, VEGF and NO in the serum of the control group and the observation group were significantly increased (P<0.05), and the levels of MDA, FIB, TNF- , CRP and ET-1 were significantly decreased (P<0.05);the trend of the above indicators was significantly higher than that of the control group (P<0.05).Conclusions: Ateplase combined with Butylphthalide in the treatment of cerebral infarction can significantly enhance the antioxidant capacity, improve blood coagulation and endothelial function, alleviate inflammation, and it has a good clinical effect.展开更多
文摘Objective:To investigate the effects of Ateprase combined with Butylphthalide on antioxidant capacity, coagulation function and related factors in patients with cerebral infarction.Methods:A total of 80 patients with cerebral infarction who were treated in department of Neurology of our hospital from June 2015 to June 2018 were randomly divided into control group and observation group, with 40 cases in each group. Patients in the control group were treated with Butylphthalidel, while patients in the observation group were treated with Ateprase combined with Butylphthalide. The levels of superoxide dismutase (SOD), serum malondialdehyde (MDA), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), vascular endothelial growth factor (VEGF), nitric oxide (NO), endothelin (ET-1), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) were measured and compared before and after treatment.Results: After treatment: the levels of SOD, APTT, PT, TT, VEGF and NO in the serum of the control group and the observation group were significantly increased (P<0.05), and the levels of MDA, FIB, TNF- , CRP and ET-1 were significantly decreased (P<0.05);the trend of the above indicators was significantly higher than that of the control group (P<0.05).Conclusions: Ateplase combined with Butylphthalide in the treatment of cerebral infarction can significantly enhance the antioxidant capacity, improve blood coagulation and endothelial function, alleviate inflammation, and it has a good clinical effect.
